Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The combination of direct weight loss and the anti-inflammatory GLP-1 mechanism (which we cover in our guide to GLP-1 agonists and joint pain) may produce benefits in joint disease that go beyond what weight loss alone would achieve
So, exogenous GLP-1R agonists have been more recently considered as a good choice for treating patients with diabetes [29]
The potential benefits of such treatment (long-term weight reduction, prevention of diabetes and diabetic complications, including cardiovascular events) need to be demonstrated in large clinical trials, but this earlier-stage population may provide unique chances to reveal benefits that cannot be shown at later stages, when the degree of tissue damage has advanced to an irreversible state
86 Patients with PSC may be completely asymptomatic (up to 44%) or have signs of advanced disease at the time of diagnosis
